• Roberto Petrioli, Stefania Rossi, Mario Caniggia, Daniele Pozzessere, Simona Messinese, Marianna Sabatino, Stefania Marsili, Pierpaolo Correale, Francesco Salvestrini, Antonio Manganelli, and Guido Francini.
• Department of Human Pathology and Oncology, University of Siena, Siena, Italy.
• Urology. 2004 Feb 1; 63 (2): 321-6.

ObjectivesTo investigate the prognostic value of some conventional bone markers and a number of other factors in terms of the survival of patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.MethodsThe data of 141 patients were analyzed to verify the influence of the following factors on survival: bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, the urinary calcium/creatinine ratio, patient age, Karnofsky performance status, pathologic grade, duration of response to primary hormonal therapy, prostate-specific antigen, hemoglobin, lactate dehydrogenase, and extent of bone disease.ResultsWhen all the variables were simultaneously analyzed using the multivariate proportional hazard model, only Karnofsky performance status (P <0.005) and duration of response to primary hormonal therapy (P <0.0001) remained statistically significant.ConclusionsThe results of this study suggest that bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, and the urinary calcium/creatinine ratio are not prognostic of survival in patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.

53 keywords...

hide…